The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (Review)

Oncology Reports

Volumn 9, Issue 1, 2002, Pages 3-9

  Kim, Ryungsa ^a   Tanabe, Kazuaki ^a   Uchida, Yoko ^a   Osaki, Akihiko ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Drug sensitivity; HER 2

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH FACTOR RECEPTOR; RECEPTOR, ERBB 2;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG RESISTANCE; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMAN; LYMPH NODES; LYMPHATIC METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0036134419     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.1.3     Document Type: Review

References (53)

1. King CR, Kraus MH and Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976, 1985. (Pubitemid 16248488)
2. Van de Vijver M, van de Bersselaar R, Deville P, et al: Amplification of the new (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 7: 2019-2023, 1987. (Pubitemid 17059197)
3. Coussens L, Yang-Feng TL, Liao Y-C, Chen E, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with new oncogene. Science 230: 1132-1139, 1985. (Pubitemid 16169997)
4. Stern DF, Heffernan PA and Weinberg RA: p185, a product of the new protooncogene is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 6: 1729-1740, 1986. (Pubitemid 16121264)
5. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
6. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994.
7. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International Breast Cancer Study Group. J Clin Oncol 10: 1049-1056, 1992.
8. Yu D, Liu B, Tan M, et al: Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-independent mechanisms. Oncogene 13: 1359-1365, 1996. (Pubitemid 26343590)
9. mdr-1 renders breast cancer cells highly resistant to Taxol. Oncogene 16: 2087-2094, 1998.
10. Pegram MD, Finn RS, Arzoo K, et al: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537-547, 1997. (Pubitemid 27384731)
11. Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595, 2001. (Pubitemid 32441364)
12. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998. (Pubitemid 28311914)
13. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575-4580, 1991.
14. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast cancer and ovarian cancer cells. Oncogene 9: 1829-1838, 1994. (Pubitemid 24194147)
15. Slamon DL, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpress HER-2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
16. Pietras RJ, Pegram MD, Finn RS, et al: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235-2249, 1998. (Pubitemid 28515376)
17. Alaoui-Jamali MA, Paterson J, Al Moustata AE, et al: The role of erbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 75: 315-325, 1997. (Pubitemid 127733182)
18. Tzahar E and Yarden Y: The ErbB-2/HER-2 oncogenic receptor of adenocarcinomas: from orphanhood to mutiple stromal ligands. Biochim Biophys Acta 1377: M25-M37, 1998. (Pubitemid 28144426)
19. Pierce JH, Arnstein P, DiMarco E, et al: Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 6: 1189-1194, 1991. (Pubitemid 21924207)
20. Robinson MJ and Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186, 1997. (Pubitemid 27135985)
21. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
22. Quenel N, Wafflat J, Bonichon F, et al: The prognostic value of c-erbB2 in priamry breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 35: 283-291, 1995.
23. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135, 1995.
24. Fehm T, Maimonis P, Weitz S, et al: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 43: 87-95, 1997. (Pubitemid 27090870)
25. Harris LN, Liotcheva V, Broadwater G, et al: Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 19: 1698-1706, 2001. (Pubitemid 32230870)
26. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992.
27. Baselga J, Seidman AD, Rosen PP, et al: HER-2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11: 43-48, 1997. (Pubitemid 27225846)
28. Sabbatini AR, Basolo F, Valentini P, et al: Induction of multidrug resistance (MDR) by transfection of MCF-10A cell line with c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer 59: 208-211, 1994. (Pubitemid 24343364)
29. Orr MS, O'Connor PM and Kohn KW: Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. J Natl Cancer Inst 92: 987-994, 2000. (Pubitemid 30469964)
30. Colomer R, Lupu R, Bacus SS, et al: erbB-2 antisense oligonucleotide inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 70: 819-825, 1994. (Pubitemid 24331071)
31. Slamon D and Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28: 13-19, 2001.
32. Thor AD, Berry DA, Budman DR, et al: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998. (Pubitemid 28439959)
33. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998. (Pubitemid 28439960)
34. Jarvinen TAH, Kononen J, Pelto-Huikko M, et al: Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 148: 2073-2083, 1996.
35. Jarvinen TAH, Tanner M, Rantanen V, et al: Amplification and detection of topoisomerase IIα associate with erbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156: 839-847, 2000. (Pubitemid 30626942)
36. Harris LN, Yang L, Liotcheva V, et al: Induction of topoisomerase II activity after erbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 7: 1497-1504, 2001. (Pubitemid 32708611)
37. Colomer R, Montero S, Lluch A, et al: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356-2362, 2000. (Pubitemid 30399203)
38. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95, 1992. (Pubitemid 23063891)
39. HER2monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744, 1996.
40. Baselga J: Current and planned clinical trials with trastuzumab (Herceptin). Semin Oncol 27: 27-32, 2000.
41. Teixeira C, Reed JC and Pratt MCA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995.
42. Huang Y, Ray S, Reed JC, et al: Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42: 73-81, 1997. (Pubitemid 27056730)
43. Child SJ, Miller MK and Geballe AP: Cell type-dependent and - independent control of HER-2/neu translation. Int J Biochem Cell Biol 31: 201-213, 1999. (Pubitemid 29094800)
44. L, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 2: 1215-1219, 1996.
45. Cdc2 kinase. Mol Cell 2: 581-591, 1998.
46. Zhang L, Lau YK, Xia W, Hortobagyi GN and Hung MC: Tyrosine kinase inhibitor emodin suppress growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5: 343-353, 1999. (Pubitemid 29085188)
47. Yu D, Suen T-C, Yan D-H, et al: Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA 87: 4499-4503, 1990.
48. Ueno NT, Yu D and Hung MC: Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 15: 953-960, 1997. (Pubitemid 27399556)
49. Hortobagyi GN, Ueno NT, Xia W, Zhang S, et al: Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effect: a phase I clinical trial. J Clin Oncol 19: 3422-3433, 2001. (Pubitemid 32642196)
50. neu. Clin Cancer Res 5: 1884-1891, 1999.
51. Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, et al: Medical applications of single-chain antibodies. Int Rev Immunol 10: 195-217, 1993.
52. Wright M, Grim J, Deshane J, et al: An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther 4: 317-322, 1997. (Pubitemid 27170724)
53. Grunt T, Dittrich E, Ofterdinger M, et al: Effect of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 78: 79-87, 1998. (Pubitemid 28276774)